Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.
Atas U, Salim O, Iltar U, Yucel OK, Kucukdiler Eroglu AH, Aslan V, Yildirim M, Dedeoglu O, Secilmis S, Ulas T, Deveci B, Karaman Gulsaran S, Geduk A, Yaman F, Pinar IE, Maral S, Sarici A, Celik S, Ogul H, Gulkan Ozkan S, Gemici A, Gunes AK, Tombak A, Yavasoglu I, Karakus V, Comert M, Toptas T, Dal MS, Saba R, Kirgizlar HO, Mehtap O, Gunduz E, Ozkalemkas F, Albayrak M, Berber I, Keklik M, Guler N, Ozkan HA, Sevindik OG, Bolaman Z, Kurtoglu E, Ayli M, Firatli Tuglular T, Altuntas F, Undar L.
Atas U, et al. Among authors: sarici a.
Turk J Haematol. 2024 Nov 6. doi: 10.4274/tjh.galenos.2024.2024.0450. Online ahead of print.
Turk J Haematol. 2024.
PMID: 39501735
Free article.